Single-Cell MRD Profiling in AML Identifies CXCR4 Expression as a Predictor of Motixafortide Response
Mission Bio
52:40
Recent advances in single-cell profiling and targeted therapy are reshaping acute myeloid leukemia (AML) management. In this webinar, we will present results from a randomized trial of CXCR4 inhibition in AML, integrating single-cell MRD analysis and biomarker stratification. We will explore how molecular heterogeneity and CXCR4 expression inform therapeutic response and relapse risk, highlighting new opportunities for personalized patient care.
Speakers
Dr. Enise Ceran
Physician Scientist
Enise Ceran is a physician scientist at University Hospital Heidelberg, Germany. She completed her medical degree at the Medical University of Vienna and is currently pursuing her clinical residency in the Medical Department V (Hematology, Oncology and Rheumatology). Enise specializes in translational research on acute myeloid leukemia (AML), with a focus on single-cell multiomics, measurable residual disease, and biomarker-driven therapy of the CXCR4-CXCL12 axis.
Jacqueline Marin
[email protected]
Replays
See all
Single-Cell MRD Profiling in AML Identifies CXCR4 Expression as a Predictor of Motixafortide Response
52:40